相关实验视频

Updated: Jan 9, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

在严重喘中,Siglec-8作为预测抗IL-5反应的生物标志物

Youngsoo Lee¹, Hyunkyung Kim², Chae Eun Lee²

¹Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.

Allergy, asthma & immunology research

|December 2, 2025

概括

血清Siglec-8水平显示出在接受抗干白素-5 (IL-5) 治疗的重症喘 (SA) 患者预测治疗反应的生物标志物,其表现优于血中乙氨基酸细胞计数.

科学领域:

肺病学和免疫学肺病学和免疫学
生物标志物发现发现
精准医学是一门精准的医学.

背景情况:

严重喘 (SA) 管理正在与生物疗法一起发展.
患者对生物制剂反应的变化凸显了对预测生物标志物的需求.
Siglec-8,表达在氨基基细胞上,是SA中的生物反应的潜在生物标志物.

研究的目的:

为了评估血清Siglec-8基线水平对SA患者对抗干白素-5 (IL-5) 治疗的临床反应的预测值.
为了将Siglec-8的预测性能与其他参数进行比较,例如血中乙氨基酸细胞计数.
评估Siglec-8在指导SA的治疗决策中的实用性.

主要方法:

分析了68名SA患者的精准医学干预重症喘研究,他们接受了抗IL-5疗法.
测量了基线血清Siglec-8水平和血中乙氨基酸细胞计数.
对6个月和12个月的临床结果的评估,将优秀反应者定义为零恶化的人.
使用多变量逻辑回归和接收机运行特征曲线分析.

主要成果:

基线血清Siglec-8水平显示出与血中乙氨基酸细胞计数相比,在预测6个月和12个月后的反应方面,诊断性能更优的趋势.
对Siglec-8的曲线下面积值为0.931 (6个月) 和0.811 (12个月的优异响应者),对比为0.836和0.628的乙氨基酸.
在6个月的抗IL-5治疗后,血清Siglec-8与血中乙氨基基酸计数的比率显著增加 (P < 0.001).

结论:

起初的血清Siglec-8水平显示了SA患者抗IL-5治疗反应的有希望的预测性表现.
西格莱克-8可以作为一个有价值的生物标志物来指导严重喘治疗选择.
建议在更大的前性研究中进行进一步验证,以确认这些发现.

关键词:

喘喘是一种在IL-5中,IL-5是最常见的.生物疗法是一种生物疗法.生物标志物生物标志物埃索诺菲尔细胞的存在受体,免疫学上的受体.治疗治疗治疗治疗治疗治疗

更多相关视频

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

相关概念视频

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...